Previous 10 | Next 10 |
home / stock / rlftf / rlftf news
Acer to receive $1 million payment to obtain exclusivity and a $4 million loan from Relief Companies working toward negotiation and execution of a definitive collaboration and license agreement by June 30, 2021 GENEVA, SWITZERLAND, and NEWTON, MA / ACCESSWIRE / January 25, 2021 / R...
GENEVA, SWITZERLAND / ACCESSWIRE / January 21, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today an...
NeuroRx, Relief Therapeutics ([[RLFTF]] +5.4%) and the Quantum Leap Healthcare Collaborative ("Quantum Leap") of San Francisco announce that NeuroRx and QLHC have signed a clinical trial participation agreement for the inclusion of Zyesami (RLF-100 aviptadil) in the I-SPY COVID-19 trial....
NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial PR Newswire RADNOR, Pa. and GENEVA , Jan. 11, 2021 /PRNewswire/ -- NeuroRx, Inc. and RELIEF THERAPEUTICS Holding ...
NeuroRx and Relief Conclude Enrollment in their Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure PR Newswire RADNOR, Pa. and GENEVA, Switzerland, Dec. 30, 2020 /PRNewswire/ -- NeuroRx, Inc. and RELIEF THERAPEU...
GENEVA, SWITZERLAND / ACCESSWIRE / December 21, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today a...
GENEVA, SWITZERLAND / ACCESSWIRE / December 18, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, announc...
Speaking to CNBC, Relief Therapeutics' ([[RLFTF]] +11.5%) Chairman Ram Selvaraju said the ongoing Phase 2b/3 trial with RLF-100 is expected to provide topline data in 1H of January, and attributed the 38,000% rise so far this year, in share price in part to its evidence of efficacy ...
NeuroRx and Relief Therapeutics Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure RADNOR, Pa. and GENEVA, Dec. 7, 2020 /PRNewswire/ -- NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX...
Relief Therapeutics has a found a new use for Vasoactive Intestinal Peptide by repackaging it as RLF-100 (Aviptadil) to now fight COVID. RLF-100 is still undergoing clinical Phase 2/3 trials but has already shown promising use in an emergency setup for critically ill patients. In ...
News, Short Squeeze, Breakout and More Instantly...
Mondobiotech Holding AG Basel Company Name:
RLFTF Stock Symbol:
OTCMKTS Market:
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call p...
GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announce...
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call point Transaction is expected to be accretive to 2024 earnings Estimated peak sales of more than $10 million annually U.S. phenylketonuria ("PKU"...